Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4601 Pembrolizumab combined with cisplatin or carboplatin and etoposide in treatment naïve advanced Merkel cell carcinoma (MCC): The phase II PANDORA Trial

Introduction: MCC is a rare and aggressive skin neuroendocrine tumour with high metastatic potential and mortality. Therapeutic options in metastatic/unresectable MCC are based on immunotherapy or platinum-based chemotherapy. However, a subgroup of patients (pts) has primary immunoresistance disease, so it would be important discover active upfront combinations. PANDORA trial [NCT 06086288] is an open-label, multicentre, single-arm phase II trial evaluating the activity and safety of pembrolizumab (PEM) combined with platinum-based chemotherapy as 1st line treatment in pts with metastatic, unresectable or recurrence MCC. Supported in part by a research grant from Investigator-Initiated Studies Program of MSD.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Cingarlini S, Di Giacomo A, Borghesani M,

Keywords: Pembrolizumab, clinical trial, Merkel cell carcinoma, chemio-immunotherapy,

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#4562 Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: The OCLURANDOM trial

Introduction: No published randomised trial investing the role of PRRT (177Lutetium-DOTA-Octreotate) in advanced progressive PaNET patients.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Walter T, Beron A, Smith D, Deandreis D,

Keywords: Pancreatic neuroendocrine, randomised phase 2 trial, Lutathera, Sunitinib,

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,